The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)
This FOA provides funding to conduct pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development to treat neurological disorders that fall under the NINDS mission. Therapeutic agents may include but are not limited to small molecules, biologics or biotechnology-derived products. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the NINDS Cooperative Research to Enable and Advance Translational Enterprises for Biologics program (CREATE Bio) program for biologics, biotechnology products, Blueprint Neurotherapeutics Network for small molecules, or other translational programs.
- Application Due Dates: June 19, 2018, October 17, 2018, February 20, 2019, June 19, 2019, October 17, 2019, February 19, 2020, June 17, 2020, October 20, 2020 and February 17, 2021
- AIDS Due Dates: Jan. 7, May 7, Sep. 7
PAR-18-761 Expiration Date May 8, 2021
Direct costs cannot exceed $499,000 in any one year . Cumulative direct costs for the entire 3-year project period may not exceed $750,000.